Effectiveness and safety of oral olanzapine treatment transitioned from rapid-acting intramuscular olanzapine for agitation associated with schizophrenia

QR Code

Effectiveness and safety of oral olanzapine treatment transitioned from rapid-acting intramuscular olanzapine for agitation associated with schizophrenia

Hideaki Katagiri,1 Masanori Taketsuna,2 Shinpei Kondo,3 Kenta Kajimoto,4 Etsuko Aoi,5 Yuka Tanji1 1Bio-Medicines, Medicines Development Unit Japan, Eli Lilly Japan K.K., Kobe, Japan; 2Statistical Sciences, Medicines Development Unit Japan, Eli Lilly Japan K.K., Kobe, Japan; 3Post Marketing Study Ma...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Katagiri H, Taketsuna M, Kondo S, Kajimoto K, Aoi E, Tanji Y
Format:	article
Langue:	EN
Publié:	Dove Medical Press 2018
Sujets:	agitation oral postmarketing surveillance study rapid-acting intramuscular olanzapine schizophrenia Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Accès en ligne:	https://doaj.org/article/2e48f8bb99f147df94bc5b0b241a6263
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Safety and effectiveness of rapid-acting intramuscular olanzapine for agitation associated with schizophrenia – Japan postmarketing surveillance study
par: Katagiri H, et autres
Publié: (2018)

Influence of olanzapine on serum prolactin levels and BMI in female patients with schizophrenia
par: Yang F, et autres
Publié: (2018)

Clinical outcomes with olanzapine long-acting injection: impact of the 3-hour observation period on patient satisfaction and well-being
par: Anand E, et autres
Publié: (2016)

Reversal of olanzapine-induced weight gain in a patient with schizophrenia by switching to asenapine: a case report
par: Okazaki K, et autres
Publié: (2017)

The effectiveness and safety of amisulpride in Chinese patients with schizophrenia who switch from risperidone or olanzapine: a subgroup analysis of the ESCAPE study
par: Liang Y, et autres
Publié: (2017)

A naturalistic comparison of the efficacy and safety of intramuscular olanzapine and intramuscular levomepromazine in agitated elderly patients with schizophrenia
par: Suzuki H, et autres
Publié: (2013)

One-Year Course of Olanzapine-Induced Diabetic Ketoacidosis: A Case Report
par: Mohammed Zain Ulabedin Adhoni, et autres
Publié: (2021)

Examining the safety, efficacy, and patient acceptability of inhaled loxapine for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults
par: Faden J, et autres
Publié: (2019)

Efficacy and safety of olanzapine/fluoxetine combination in the treatment of treatment-resistant depression: a meta-analysis of randomized controlled trials
par: Luan S, et autres
Publié: (2017)

Efficacy and safety of olanzapine for treatment of patients with bipolar depression: Chinese subpopulation analysis of a double-blind, randomized, placebo-controlled study
par: Wang G, et autres
Publié: (2016)

Profile of olanzapine long-acting injection for the maintenance treatment of adult patients with schizophrenia
par: Rosaria Di Lorenzo, et autres
Publié: (2010)

Associations of C-Reactive Protein, Free Triiodothyronine, Thyroid Stimulating Hormone and Creatinine Levels with Agitation in Patients with Schizophrenia: A Comparative Cross-Sectional Study
par: Li C, et autres
Publié: (2021)

Effect of amisulpride, olanzapine, quetiapine, and aripiprazole single administration on c-Fos expression in vasopressinergic and oxytocinergic neurons of the rat hypothalamic supraoptic nucleus
par: Kiss Alexander, et autres
Publié: (2020)

Pain from intramuscular vaccine injection in adults
par: Sahngun Nahm,Francis, et autres
Publié: (2012)

Long-acting injectable antipsychotics: focus on olanzapine pamoate
par: JP Lindenmayer
Publié: (2010)

Long-Acting Injectable Drugs in the Maintenance Therapy of Patients with Schizophrenia
par: Natalia N. Petrova, et autres
Publié: (2020)

Switching to olanzapine long-acting injection from either oral olanzapine or any other antipsychotic: comparative post hoc analyses
par: Ciudad A, et autres
Publié: (2013)

Assessment of the Effects of Dietary Vitamin D Levels on Olanzapine-Induced Metabolic Side Effects: Focus on the Endocannabinoidome-Gut Microbiome Axis
par: Armita Abolghasemi, et autres
Publié: (2021)

Long-term functional improvements in the 2-year treatment of schizophrenia outpatients with olanzapine long-acting injection
par: Ascher-Svanum H, et autres
Publié: (2014)

Antipsychotic monotherapy among outpatients with schizophrenia treated with olanzapine or risperidone in Japan: a health care database analysis
par: Takahashi M, et autres
Publié: (2012)

c-Fos and FosB/ΔFosB colocalizations in selected forebrain structures after olanzapine, amisulpride, aripiprazole, and quetiapine single administration in rats preconditioned by two different mild stressors sequences
par: Kiss Alexander, et autres
Publié: (2020)

Exploring the long-term safety of asenapine in adults with schizophrenia in a double-blind, fixed-dose, extension study
par: Durgam S, et autres
Publié: (2017)

Demonstration of Intramuscular Artery and Nerve Distribution in the Same Whole Mount Gracilis Muscle by Different Colors
par: An,Xiaochun, et autres
Publié: (2016)

Spatial relationship between the c-Fos distribution and enkephalinergic, substance P, and tyrosine hydroxylase innervation fields after acute treatment with neuroleptics olanzapine, amisulpride, quetiapine, and aripiprazole in the rat septum
par: Kiss Alexander, et autres
Publié: (2019)

Agitated behaviors among elderly people with dementia living in their home in Taiwan
par: Huang HL, et autres
Publié: (2018)

A commentary on the efficacy of olanzapine for the treatment of schizophrenia: the past, present, and future
par: Citrome L, et autres
Publié: (2019)

Attitudes toward long-acting injectable antipsychotics among patients with schizophrenia in Japan
par: Sugawara N, et autres
Publié: (2019)

Taiwan Expert Consensus Recommendations for Switching to Aripiprazole Long-Acting Once-Monthly in Patients with Schizophrenia
par: Chih-Sung Liang, et autres
Publié: (2021)

Dexmedetomidine for the management of postictal agitation after electroconvulsive therapy with S-ketamine anesthesia
par: Aksay SS, et autres
Publié: (2017)

Gabapentin adjunctive to risperidone or olanzapine in partially responsive schizophrenia: an open-label pilot study
par: Adel Gabriel
Publié: (2010)

Overall Distribution Pattern of the Intramuscular Nerves of the Extraocular Muscles and its Clinical Implications
par: Zhou,Guoyan, et autres
Publié: (2021)

Role of 3-monthly long-acting injectable paliperidone in the maintenance of schizophrenia
par: Brasso C, et autres
Publié: (2017)

The effects of surgical treatment and sclerotherapy for intramuscular venous malformations: a comparative clinical study
par: Yun Hyun Kim, et autres
Publié: (2021)

Real-World Outcomes of Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration: A Large-Scale Postmarketing Surveillance in Korea
par: Ryu G, et autres
Publié: (2021)

Successful Treatment of Delusional Infestation with Olanzapine Depot
par: Javor Vouk-Kamenski, et autres
Publié: (2021)

Reduced serum paraoxonase 1 (PON1) activity in patients with schizophrenia treated with olanzapine but not quetiapine
par: &Uuml;nsal C, et autres
Publié: (2013)

Hypomania after augmenting venlafaxine and olanzapine with sarcosine in a patient with schizophrenia: a case study
par: Strzelecki D, et autres
Publié: (2015)

Second-generation long-acting injectable antipsychotics in schizophrenia: patient functioning and quality of life
par: Montemagni C, et autres
Publié: (2016)

Electroencephalogram Signatures of Agitation Induced by Sevoflurane and Its Association With Genetic Polymorphisms
par: Shuai Zhao, et autres
Publié: (2021)

Postmarket surveillance of 3D-printed implants for sacroiliac joint fusion
par: Cher D, et autres
Publié: (2018)